Followers | 126 |
Posts | 5401 |
Boards Moderated | 0 |
Alias Born | 06/09/2020 |
Wednesday, October 26, 2022 9:19:38 AM
Who has researched in groundbreaking immunotherapy the last two decades ... or has she in fact instead been an involuntary victim to a grand scheme of collusion instigated by the woman in charge of the Enron scandal in the 1990's, Linda Powers? A scam setup long before the woman in question actually entertained the place with her own presence and which she is now bringing to fruition by creating her very own CDMO with funds from the company, who has been funding the research for more than 20 years and thus scamming all of the 18 other employees in her company for their money invested in shares and options?
Every puzzle seems to fit perfectly, when one comes to think of it and looking at the last 15 years of clinical trial. Looking at the combo trial with Poly-ICLC, which Linda Liau seems to believe her placebo substance can make more than 50% of all patients live more than 100 months. Looking at the combo trial with Keytruda, which has become the UCLAs most prestigious cancer research project, with Merck delivering Keytruda for free.
And tonight Linda Liau is at it again. An Honored Guest Lecture in her name ending a day of talks with her own "The Promise of Immunotherapy for Treatment of Glioblastoma”.
It's quite the scheme, because while Linda Powers actually tries to scam Linda Liau, by not knowing her substance is actually just a placebo, Linda Liau HAS actually developed a fully working substance, which she plans on using herself, without Linda Powers knowing about it.
It's true! It's been fully confirmed by several non invested retailers in said researching company.
A Mata Hari. A double agent. And MacGuffin starring as .... DCVax-L.
My God, this is unbelievable. We have all the ingredients for a Hitchcock movie and still we have yet to see the ending.
I'm so excited!
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
FEATURED DaBaby and Stunna 4 Vegas's "NO DRIBBLE" Joins Music Licensing, Inc.'s Portfolio • Jun 7, 2024 10:15 AM
Mushrooms Inc. (OTC: MSRM) Announces Significant Share Buy Back by the Board Director and New Strategic Initiatives. • MSRM • Jun 5, 2024 1:32 PM
Hydromer Announces Launch of HydroThrombX Medical Device Coating Technology • HYDI • Jun 5, 2024 10:24 AM
Dr. Michael Dent Finances $1 Million to Drive HealthLynked's Healthcare Transformation • HLYK • Jun 5, 2024 8:00 AM
Avant Technologies Enters Binding LOI to Purchase Dozens of High-Performance, Immersible, AI-Powered Servers • AVAI • Jun 5, 2024 8:00 AM
IQST - iQSTEL Announces $290 Million 2024 Annual Revenue Forecast • IQST • Jun 4, 2024 1:43 PM